&sq=Qlik&lang=&file=File:Grail_logo.png){kind=logo} | |
| Company type | Public |
|---|---|
| Nasdaq: GRAL | |
| Industry | Biotechnology |
| Founded | 2015 |
| Headquarters | , United States |
| Products | Galleri test |
| Website | grail |
Grail (styled GRAIL) is an American biotechnology company in Menlo Park, California. It was previously a subsidiary of Illumina started as a startup seeking to develop an early cancer screening test for people who do not have symptoms.[1] Grail was spun-out from Illumina on June 24, 2024.
Their liquid biopsy (also called multi-cancer early detection test[2]) which was launched in June 2021 and is called the Galleri test, detects fragments of DNA in a blood sample via next-generation sequencing, which identifies DNA methylation, distinct patterns of which are associated with particular cancers, potentially allowing for the early detection of cancer and providing information of the origin of the cancer. It is one of three multi-cancer screening tests under investigation; the other two being the CancerSEEK assay and the PanSeer assay.
- ^ Simon, Francoise; Glen Giovannetti (2017). "1. Digital evolution of biotechnology". Managing Biotechnology: From Science to Market in the Digital Age. John Wiley & Sons. p. 21. ISBN 978-1-119-21617-9.
- ^ Pyzocha, Natasha J. (October 2022). "Galleri Test for the Detection of Cancer". American Family Physician. 106 (4): 459–460. ISSN 1532-0650. PMID 36260909.